Status:

COMPLETED

Regulation of FGF21 by Nutritional Challenges

Lead Sponsor:

Beth Israel Deaconess Medical Center

Conditions:

Fasting

Non-alcoholic Fatty Liver Disease (NAFLD)

Eligibility:

All Genders

18-60 years

Phase:

NA

Brief Summary

The purpose of this study is to examine how acute nutritional challenges affect levels of several proteins involved in metabolism. These proteins will be measured in blood and fat tissue. This study ...

Detailed Description

Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to 5 different sweet beverages, separated by 2 ...

Eligibility Criteria

Inclusion

  • 72-hour fast in healthy volunteers (Study Arm A):
  • Age 18-50 years
  • Body Mass Index 21-26 kg/m\^2
  • Ability to give informed consent
  • Ability to follow verbal and written instructions in English

Exclusion

  • Type 1 or Type 2 diabetes mellitus diagnosed according to the American Diabetes Association criteria
  • Coronary heart disease (history of myocardial infarction, unstable angina pectoris, or congestive heart failure)
  • Tobacco, marijuana, or intravenous drug use within 1 year of screening visit
  • Recent weight change (\>3 kg within 6 months of screening visit)
  • Malignancy treated with chemotherapy within past 3 years
  • History of depression, psychosis, or other psychiatric illness requiring hospitalization
  • History of hyperthyroidism
  • Renal insufficiency (creatinine clearance \< 50 ml/min)
  • Transaminases \> 2X above the normal range
  • Known liver disease
  • Pregnancy within 12 months of screening visit
  • Lactation within 12 months of screening visit
  • Failure to use medically approved contraceptive methods (oral contraceptive, 2 barrier methods, surgical sterilization)
  • History of an eating disorder (anorexia, bulimia, or laxative abuse)
  • History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling)
  • New diagnosis of hypothyroidism within 1 year of screening visit or change in dose of thyroid hormone within 3 months of screening visit
  • History of alcohol abuse within the past 3 years
  • History of keloid formation
  • History of allergy to lidocaine or marcaine
  • Use of plavix, coumadin, or heparin
  • 72-hour fast or hypocaloric diet in subjects with non-alcoholic fatty liver disease (NAFLD) (Study Arms B \& C):
  • Inclusion Criteria:
  • Age 18-60
  • BMI 25-45 kg/m\^2
  • Known nonalcoholic fatty liver disease based on liver biopsy
  • Ability to give informed consent
  • Ability to follow verbal and written instructions in English

Key Trial Info

Start Date :

July 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 31 2023

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00968747

Start Date

July 1 2009

End Date

July 31 2023

Last Update

August 14 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215